Bessemer Group Inc. reduced its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 67.9% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 154,389 shares of the medical instruments supplier’s stock after selling 326,182 shares during the period. Bessemer Group Inc. owned approximately 0.21% of C.R. Bard worth $48,804,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of BCR. Cribstone Capital Management LLC bought a new stake in shares of C.R. Bard during the first quarter valued at $130,000. Contravisory Investment Management Inc. boosted its stake in shares of C.R. Bard by 349.2% in the first quarter. Contravisory Investment Management Inc. now owns 548 shares of the medical instruments supplier’s stock valued at $136,000 after buying an additional 426 shares during the last quarter. Whittier Trust Co. boosted its stake in shares of C.R. Bard by 7.7% in the first quarter. Whittier Trust Co. now owns 591 shares of the medical instruments supplier’s stock valued at $147,000 after buying an additional 42 shares during the last quarter. ClariVest Asset Management LLC bought a new stake in shares of C.R. Bard during the first quarter valued at $148,000. Finally, SRS Capital Advisors Inc. boosted its stake in shares of C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after buying an additional 4 shares during the last quarter. 77.14% of the stock is owned by institutional investors.
Shares of C.R. Bard, Inc. (NYSE:BCR) traded up 0.04% on Tuesday, reaching $321.00. The company’s stock had a trading volume of 251,031 shares. The company has a market cap of $23.33 billion, a P/E ratio of 42.14 and a beta of 0.59. The company’s 50 day moving average price is $319.14 and its 200 day moving average price is $284.89. C.R. Bard, Inc. has a 12-month low of $203.63 and a 12-month high of $323.27.
C.R. Bard (NYSE:BCR) last announced its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The company had revenue of $979.70 million for the quarter, compared to the consensus estimate of $976.53 million. During the same quarter in the previous year, the business earned $2.54 EPS. C.R. Bard’s revenue was up 5.2% compared to the same quarter last year. Analysts forecast that C.R. Bard, Inc. will post $11.84 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Friday, August 4th. Investors of record on Monday, July 24th were issued a dividend of $0.26 per share. The ex-dividend date of this dividend was Thursday, July 20th. This represents a $1.04 dividend on an annualized basis and a yield of 0.32%. C.R. Bard’s dividend payout ratio is presently 13.67%.
COPYRIGHT VIOLATION NOTICE: “C.R. Bard, Inc. (NYSE:BCR) Shares Sold by Bessemer Group Inc.” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/08/15/bessemer-group-inc-has-48-80-million-stake-in-c-r-bard-inc-nysebcr-updated.html.
Several brokerages have recently weighed in on BCR. Cowen and Company increased their price target on C.R. Bard from $240.00 to $317.00 and gave the company a “market perform” rating in a research note on Monday, April 24th. BidaskClub raised C.R. Bard from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 8th. Zacks Investment Research raised C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price target for the company in a research note on Tuesday, June 6th. Jefferies Group LLC increased their price target on C.R. Bard from $237.00 to $317.00 and gave the company a “hold” rating in a research note on Monday, April 24th. Finally, Wells Fargo & Company cut C.R. Bard from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 25th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company. C.R. Bard has a consensus rating of “Hold” and a consensus price target of $285.67.
In related news, insider John P. Groetelaars sold 23,687 shares of the business’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the transaction, the insider now owns 31,445 shares in the company, valued at approximately $10,022,464.85. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.80% of the stock is owned by insiders.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
